Novartis confident of Zolgensma supply, calls $2 million price 'speculation'

Novartis is confident it has adequate production capacity for its Zolsgensma gene therapy should regulators this month approve the drug for multiple forms of the genetic disease spinal muscular atrophy, the Swiss drugmaker said on Wednesday.